Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Malignant Solid Neoplasm: early-phase trial registry
9 of 60 indexed Refractory Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #235 of 28,707 conditions by registered trial count.
60 US clinical trials · 9 currently recruiting · #235 of 28,707 conditions by registered trial count
Refractory Malignant Solid Neoplasm: 60 US clinical trials tracked, 9 recruiting.
Refractory Malignant Solid Neoplasm is the subject of 60 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 59 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 45 of these trials.
Enrollment posture brief
Registry condition refractory-malignant-solid-neoplasm
OPEN 9 | RECR 15% | LATE 0 | EARLY 59 | RANK #235 | SPON 45
Volume-matched condition peers
Nearest open-share peer: Coronary Heart Disease (15% recruiting · 20 trials)
Refractory Malignant Solid Neoplasm lists 9 open slots (15% of 60 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Malignant Solid Neoplasm is recruiting below its size-band peers.
9 of 60 indexed trials (15%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Malignant Solid Neoplasm research.
National Cancer Institute (NCI) accounts for 45 of 60 trials (75%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Malignant Solid Neoplasm trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 60 trials that report a genuine target (sentinel values excluded). 58 of those (96.7%) plan for fewer than 100 participants.
-
Refractory Malignant Solid Neoplasm research is mostly interventional.
60 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
60 total, page 2 of 2
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
NCT06303167
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
NCT04197713
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
NCT06390826
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
NCT04439266
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
NCT04439253
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
NCT04439357
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02159989
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
NCT02323880
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Children's Oncology Group
NCT03320330
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT02780804
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 26 |
| Phase 2 | 33 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Malignant Solid Neoplasm page
60 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Refractory Malignant Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Refractory Malignant Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Malignant Solid Neoplasm condition card totals 60 registered trials; most-linked intervention Biospecimen Collection; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.